MORRIS PLAINS, N.J., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the issue of U.S. Patent No. 7,666,400 covering PEGylated therapeutic agents that are constructed using the company’s and its majority-owned subsidiary, IBC Pharmaceuticals, Inc’s., proprietary dock-and-lock (DNL) technology.
